Introduction
Immune reconstitution inflammatory syndrome (IRIS) is a term used to describe the paradoxical worsening of a pre-existing infection or the presentation of a previously undiagnosed condition in HIV-infected patients soon after commencement of antiretroviral therapy (ART) [1] . Most cases of IRIS emerge within the first few weeks to few months of ART, at a time when morbidity and mortality still remain high and frequently in patients with severe CD4 lymphopenia who remain vulnerable to opportunistic diseases. It is thus crucial to distinguish IRIS from acquisition of new opportunistic infections, medication toxicities and noninfectious complications of HIV.
There are currently no widely accepted definitions of IRIS. The International Network for Studies in HIVassociated IRIS (INSHI) has published a definition for tuberculosis (TB)-IRIS [2] and other clinical trial networks use their own consensus definitions. Paradoxical IRIS is diagnosed in patients with a known infection, who experience clinical improvement after starting appropriate antimicrobial therapy, but after ART commencement they deteriorate clinically despite evidence of successful suppression of HIV plasma viremia. In paradoxical IRIS, viable organisms may not be present at the site of infection and cultures can be sterile. In unmasking IRIS, patients are diagnosed with the infectious condition after starting ART and an inflammatory component either topical or systemic may be prominent in their presentation (for example Mycobacterium avium lymphadenitis in a patient without known mycobacterial infection at prior to ART).
Because of the complexity of clinical presentations in hosts who are still severely immunocompromised, and the fact that IRIS is a diagnosis of exclusion, there is a great need for biomarkers to help in predicting and diagnosing IRIS. In recent years it has become apparent that biomarkers reflecting the immunologic consequences of HIV infection may have additive value to CD4 T-cell counts and HIV plasma viremia as prognostic indicators [3] . Data from the Strategies in Management of Antiretroviral Therapies (SMART) study indicated that IL-6, D-dimer and C-reactive protein (CRP) could help classify patients at risk for all-cause morbidity and mortality [3] . For opportunistic diseases specifically, IL-6 and CRP several months prior to the event were of significant prognostic value [4 ] . Other studies have since confirmed and expanded on these findings including cohorts of ART-naïve patients [5 ,6] . Studies on the pathogenesis of IRIS should focus on demonstrating clinically applicable biomarkers that could assist in identifying patients at risk and in differentiating IRIS from alternate diagnoses.
Pathogenesis of immune reconstitution inflammatory syndrome: nonpathogenspecific pathways
The immunopathogenesis of IRIS remains unclear but is currently intensely investigated. On the basis of the clinical observations, it appears that presence of pathogens and severe CD4 lymphopenia with potential contribution of genetic factors can lead to the dysregulated immune response that is recognized as IRIS [7, 8] .
Many retrospective and prospective studies have concluded that one of the main clinical predictors of IRIS is severe CD4 T-cell lymphopenia prior to ART initiation [9] . Animal and human data show that T lymphocytes respond to lymphopenia by enhanced homeostatic proliferation driven by both cytokines such as IL-7 and IL-15 as well as T-cell receptor (TCR) triggering by self or other antigens [10] [11] [12] [13] [14] . In animal models, profound T-cell proliferation in the presence of foreign antigens can significantly skew the T-cell regeneration towards pathogen-specific T cells [15] . In a study of patients with graft-versus-host disease (GVHD), elevated serum levels of IL-7 were observed compared with controls without GVHD [16] and higher serum IL-7 levels were also found in a study of IRIS patients compared with their controls with similar CD4 T-cell counts [17 ] . The role of IL-7 in IRIS may need to be further investigated.
Another important predictor of IRIS is pre-existing opportunistic infection. Suppressed CD4 T-cell function can lead to ineffective pathogen clearance and high antigen load. Reversal of the functional defect, as happens with ART, may lead to dysregulated inflammatory responses. Perhaps the best example of the role of functional T-cell defect as opposed to pure immunodeficiency comes from the non-HIV literature. Clifford et al. [18 ] reviewed 28 cases of progressive multifocal leukoencephalopathy (PML) that occurred in patients with multiple sclerosis who received natalizumab monotherapy. Natalizumab is a monoclonal antibody that blocks the a4b7 and a4b1 integrins preventing normal extravasation of leukocytes from the bloodstream and leading to reactivation of JC and BK viruses [19] and clinical PML [20, 21] . Patients who developed PML underwent plasma exchange or immunoabsorption and developed PML-IRIS, which required use of corticosteroid therapy [18 ] . This demonstrates that IRIS can occur upon reversal of functional suppression of T lymphocytes even in the absence of lymphopenia.
Innate immune responses may also be playing a role regardless of the specific pathogen involved. This was demonstrated in recent studies in both TB as well as hepatitis B-associated IRIS [22 ,23 ] . Markers of antigen-presenting cell activation such as IL-6 that induces CRP production may prove to be of clinical utility in IRIS. CRP was found in a small study to be elevated prior to ART in patients who developed IRIS [24 ] and was higher in patients with TB-IRIS in another study [25] . In an older study, plasma levels of IL-6 were found to be elevated in a group of patients with IRIS associated with herpesviruses (Cytomegalovirus (CMV) retinitis, cutaneous zoster and perianal herpes) and these elevated levels persisted and progressed for up to 4 years [26] . In addition, peripheral blood mononuclear cells (PBMCs) from HIV patients with a history of IRIS produced higher amounts of IL-6 and sIL-6R than PBMC of HIV patients who did not develop IRIS following commencement of ART [27] .
Recently, it was proposed that interaction of highly activated T cells in HIV with monocytes expressing PD-1 leads to high IL-10 production by monocytes and functional T-cell suppression [28 ] . Antonelli et al. [17 ] showed that patients who develop IRIS have higher PD-1 expression on CD4þ T cells prior to ART initiation. It is feasible that decreases of these PD-1-PD-L interactions after suppression of HIV viremia results in lower IL-10 production and reversal of T-cell suppression. Most studies to date though have failed to find a difference of IL-10 levels in IRIS patients compared with their controls.
Pathogenesis of immune reconstitution inflammatory syndrome: pathogen-specific pathways, mycobacteria
The clinico-pathological manifestations of augmented pathogen-specific immune responses in IRIS can vary greatly for each type of pathogen and, therefore, immune responses may be different for each pathogen. Currently, the most comprehensive data are available for IRIS associated with Mycobacterium tuberculosis infection.
Disease associated with M. tuberculosis infection in HIV patients who have recently commenced ART presents in one of two ways. Patients with treated TB may experience a recurrence or exacerbation of inflammation at sites of previous disease and/or inflammation at sites previously unaffected by TB. The inflammatory response is often atypical for TB in the context of HIV/AIDS, especially the severity of inflammation in affected tissues and systemically. Consequently, this condition has been referred to as TB-IRIS. In contrast, disease resulting from unrecognized, and therefore untreated, M. tuberculosis infection after commencement of ART usually has a presentation that is more like typical TB and has been referred to as ARTassociated TB [29] . Both TB-IRIS and ART-associated TB appear to be a consequence of augmenting immune responses against M. tuberculosis antigens, though other causes of TB presenting after ART should always be considered, including drug-resistant M. tuberculosis infection and persistent immunodeficiency.
Analysis of various biomarkers in patients with TB-IRIS and ART-associated TB has not only provided evidence that these conditions result from augmenting immune responses against M. tuberculosis antigens but also that the type of immune response may differ and be a determinant of disease presentation. Both TB-IRIS and ARTassociated TB have been associated with an increase in the number of circulating T cells that produce interferong (IFN-g) in response to M. tuberculosis antigens, which has been demonstrated using enzyme-linked immunospot (ELISOT) or whole blood IFN-g release assays (IGRAs) and flow cytometric analysis of intracellular cytokine production in T cells.
Using ELISPOT assays, Bourgarit et al. [30] undertook a 24-week longitudinal study on seven patients who developed TB-IRIS and reported higher numbers of IFN-g þ T cells reactive with purified protein derivative (PPD) of M. tuberculosis compared with controls. Similar findings were demonstrated in a small number of patients from Malaysia [31] . In a follow-up study by Bourgarit et al.
[32 ] on 11 patients with TB-IRIS, it was shown by flow cytometry that the IFN-g þ T cells were activated effector memory CD4 þ T cells that also produced TNF-a.
In a study on 35 South African patients with TB-IRIS, Meintjes et al. [25] used ELISPOT assays to examine IFN-g þ T cells. A cross-sectional assessment of data at the time of TB-IRIS demonstrated that median numbers of IFN-g þ T cells reactive with PPD, the secreted antigen ESAT-6 and the heat shock proteins Acr1 and Acr2 were increased compared with controls. However, responses were very heterogeneous and some controls also had increased numbers of antigen-reactive T cells. Furthermore, longitudinal analyses over 8 weeks showed very variable responses and few differences between cases and controls. Studies of T-cell responses to M. tuberculosis antigens in patients with TB-IRIS therefore suggest that IFN-g þ T cells reactive with PPD and particular heat shock proteins contribute to the immunopathogenesis of this condition. However, it also appears that the activity of these cells is not a sufficient explanation for the immunopathology that is observed in all patients. There are some data indicating that increased serum levels of type 1 helper T cell (Th1) cytokines, such as IFN-g, interleukin IL-2 and IL-12, and proinflammatory cytokines, such as IL-6 and tumor necrosis factor (TNF)-a, are associated with the immunopathology [30] . In addition, a recently reported study suggests that innate immune responses to M. tuberculosis are involved. Oliver et al. [23 ] assayed mediators of innate immune responses in plasma from unstimulated whole blood IGRAs obtained from Cambodian patients with TB-IRIS and controls, who had also been assessed for antigen-induced IFN-g production [33 ]. TB-IRIS was associated with increased production of IL-18, a macrophage-derived inducer of IFN-g that contributes to protective immune responses against M. tuberculosis [35, 36] , and persistently increased production of CXCL10 [also known as IFN-g inducible protein-10 (IP-10)], which is chemotactic for effector T cells [37] . In addition, production of CCL2 [also known as monocyte chemotactic protein 1 (MCP-1)] was lower in patients with TB-IRIS. These findings require confirmation, but a preliminary interpretation is that impaired monocyte chemotaxis resulting from CCL2 deficiency contributes to a higher mycobacterial load, whereas increased IL-18 and CXCL10 production augment effector T-cell responses against M. tuberculosis antigens. Further evidence suggesting that lower immune responses against M. tuberculosis may be a risk factor for TB-IRIS is provided by observations that plasma levels of antibodies to PGL-Tb1 [38] and the frequency of subpopulations of gd þ T cells [32 ] are both lower before ART is commenced.
The immune response in ART-associated differs from TB-IRIS in that an adaptive immune response mediated primarily against RD1 antigens during the first few weeks of ART appears to predominate [33 ] . In addition, Oliver et al. [23 ] demonstrated that IL-18 production was higher in ART-associated TB than in TB-IRIS and that CXCL10 or CCL2 production was not significantly different from controls. One interpretation of these data is that ART-associated TB is characterized by a predominantly adaptive immune response against secreted antigens of live mycobacteria, such as ESAT-6, whereas TB-IRIS is characterized by a combination of innate and adaptive immune responses against antigens of nonviable mycobacteria, such as PPD and heat shock proteins.
Immunological studies in patients with IRIS associated with nontuberculous mycobacterial infection also indicate that T-cell responses against mycobacterial antigens are augmented [39, 40] .
Pathogenesis of immune reconstitution inflammatory syndrome: pathogen-specific pathways, cryptococcal disease
Disseminated cryptococcal disease is frequently associated with IRIS. The pathogenesis of the inflammatory response in cryptococcal IRIS has been investigated mainly in patients who develop cryptococcal meningitis IRIS (CM-IRIS).
A small study found that plasma IgG antibody responses and T-cell IFN-g responses to cryptococcal mannoprotein peaked at the time of CM-IRIS and were 10-fold higher than that seen in non-IRIS patients or healthy controls [31] . Higher proportions of regulatory T cells also peaked at the time of IRIS and were higher than in non-IRIS patients.
Boulware et al. [41 ] prospectively studied 85 HIV þ Ugandan patients who survived to commence ART a median of 5 weeks after diagnosis of cryptococcal meningitis, and examined markers of inflammation in cerebrospinal fluid (CSF) of patients with and without CM-IRIS. Twenty-seven patients (32.5%) developed CM-IRIS after a median of 8 weeks on ART and 5 developed culture-positive CM relapse. The 27 patients who developed IRIS had less inflammation in their CSF at cryptococcal meningitis diagnosis than patients who did not subsequently develop IRIS, with decreased levels of CSF leucocytes and protein and lower levels of IFN-g and the proinflammatory cytokines IL-6, IL-8 and TNFa. Initial CSF cryptococcal antigen titers, quantitative cryptococcal cultures and glucose were comparable. Only 25% of those with prominent CSF inflammation [white blood cell (WBC) >25 cells/ml, protein >50 mg/dl] at time of initial diagnosis developed CM-IRIS compared with 71% of those below both thresholds [41 ] .
A strong CSF Th1 response was subsequently seen in those who developed IRIS, with a three-fold elevation in IFN-g and TNF-a levels from baseline as well as twofold increases in vascular endothelial growth factor (VEGF) and eotaxin (CCL11) levels. In terms of differentiating CM-IRIS from cryptococcal meningitis relapse, CSF levels of proinflammatory cytokines [IFN-g, TNFa, G-CSF, VEGF and eotaxin (CCL11)] were increased significantly from baseline in those with CM-IRIS but not in those with culture-positive cryptococcal meningitis relapse [41 ] . The results of this study suggested that CM-IRIS pathogenesis principally involved a proinflammatory cytokine response including Th1 cytokines [41 ] .
In another study from Cape Town in 65 patients of whom 11 (17%) developed CM-IRIS at a median of 29 days from start of ART [42] , CSF proinflammatory cytokines such as IFN-g, TNF-a and IL-6 did not differ significantly between first diagnosis with cryptococcal meningitis and subsequent CM-IRIS. Patients who developed IRIS did, however, have a more rapid rise of CD4 cell count from baseline to 6 months [42] .
Pathogenesis of immune reconstitution inflammatory syndrome: pathogen-specific pathways, viral diseases
Hepatotoxicity as manifested by elevated liver function tests is not uncommon after initiation of ART in HIV/ HBV-infected patients [43] . In many cases this is likely to be due to IRIS, although the pathogenesis is often not clear. One study of 36 HIV/HBV coinfected patients who were commenced on a HBV-active ART regimen as part of a randomized controlled trial, found that hepatic flaredefined as ALT levels greater than five times upper limit of normal or above 200 IU/ml higher than baselineoccurred in eight patients (22.2%) and was associated with increased plasma levels of the immune mediators CXCL 10, sCD30, IL-18 and CCL-2 [22 ] . The flare was also associated with higher levels of HBV-DNA and HIV-RNA prior to ART initiation and elevated levels of CXCL 10 and IL-18 compared with controls. The authors suggested that the association of CXCL 10 and IL-18 with hepatic flare provides evidence that IFN-g may mediate HBV-related IRIS in a manner similar to TB and cryptococcal IRIS [22 ] .
Immune reconstitution inflammatory syndrome has also been reported in association with all of the herpesviruses that are opportunistic pathogens in patients with HIV infection. Recent data are available mainly for Kaposi's sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8) from studies conducted in Africa. The seroprevalence of KSHV infection is particularly high in sub-Saharan Africa and paradoxical worsening of stable Kaposi's sarcoma or new presentation of Kaposi's sarcoma is a well recognized presentation of IRIS (KS-IRIS).
Letang et al. [44 ] prospectively followed 69 consecutive HIV-infected adults, 64 of whom were KSHV seropositive and 5 KSHV sero-negative but with clinical Kaposi's sarcoma. Of these, eight (11.6%) developed KS-IRIS (four unmasking and four paradoxical) at a median time of 13.8 weeks after commencing ART. The eight KS-IRIS cases showed a more pronounced decrease in plasma KSHV DNA levels post-ART as well as an increase in median KSHV-specific antibody levels from baseline compared with the Kaposi's sarcoma patients who did not develop IRIS [44 ] . These findings support the hypothesis that KS-IRIS may be partly explained by a KSHV-specific immune response that reduces KSHV replication while promoting paradoxical cellular proliferation with Kaposi's sarcoma progression [44 ] . The same study identified pre-ART markers predictive of KS-IRIS including detectable KSHV DNA, higher plasma HIV viremia and haematocrit below 30%.
Another study was conducted on 33 ART-naive clade C HIV-infected patients with biopsy-confirmed Kaposi's sarcoma randomized to receive ART alone or ART and chemotherapy. KSHV-specific T-cell responses became increasingly stronger in both groups after 5 months of ART. In those treated with ART and chemotherapy a pronounced decline in KSHV DNA levels was reported compared to those just treated with ART suggesting a direct effect on KSHV by the chemotherapeutic agents [45] .
Conclusion
Studies of IRIS immunopathogenesis highlight a component of both innate and adaptive immune activation with converging as well as distinct pathways depending on the underlying pathogen (Fig. 1) . Better understanding of IRIS pathogenesis could help identify biomarkers that may assist in identifying patients at risk for paradoxical IRIS who may require closer monitoring, as well 508 Biomarkers of outcomes of disease, treatment and complications
Figure 1 The immune reconstitution inflammatory syndrome (IRIS) results from the reversal of immunosuppression caused by HIV infection
IRIS is characterized by innate and adaptive immune responses to dead or live pathogens that lead to the release of cytokines and chemokines, which may differ for different types of pathogen. The effects of the cytokines and chemokines produced may include enhancement of Th1 responses (IL-18, IFNg), recruitment of T cells and NK cells to sites of inflammation (CXCL 10) and production of inflammatory molecules such as CRP (IL-6). One or more of these molecules could be candidate biomarkers for IRIS.
as patients with occult infections who may benefit from further diagnostic work-up to prevent unmasking IRIS. In addition, biomarkers such as CRP, INF-g and IP-10 may prove useful in the diagnosis of IRIS episodes. 
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